41 research outputs found

    Effects of Supplying Water with Varying Levels of Total Dissolved Solids and Sulfates to Steers During the Growing Period on Subsequent Finishing Performance

    Get PDF
    Previous results have shown that water with elevated total dissolved solids (TDS) and sulfates was detrimental to performance of growing steers. The objective of this study was to determine finishing performance of steers that had previously received different levels of water quality during the growing period. In yr 1, 78 steers (824 lb) were assigned to one of eight pens (2-4 pens/treatment) based on water supplied during the 84-d growing period. Water TDS and sulfates during growing were: 1) 1,020 and 400; 2) 4,840 and 3,090; and 3) 6,190 and 3,950 ppm of TDS and sulfates, respectively. In yr 2, 75 steers (840 lb) that were previously supplied water during a 104-d growing period averaging: 1) 1,230 and 440; 2) 2,930 and 1,730; 3) 4,720 and 2,920; and 4) 7,270 and 4,650 ppm of TDS and sulfates respectively, were received and fed in one pen. In both years, all steers were fed a common finishing diet and had access to rural water. In yr 1, steers receiving treatment 1 had higher (P \u3c 0.10) ADG and DMI compared to treatments 2 and 3 during the previous growing period. During the initial 28-d of finishing, treatments 2 and 3 had higher (P \u3c 0.10) ADG than treatment 1. Steer DMI was not different (P = 0.19) between treatments during the first 28-d. Over the entire 126-d finishing trial, ADG, DMI and carcass characteristics were not different due to treatment (P \u3e 0.10). In yr 2, there was a quadratic decline in ADG with increasing TDS (P \u3c 0.05) during the previous growing phase, resulting in treatment 4 have lower initial weight (P \u3c 0.05) compared to treatments 1, 2, and 3. During the first 28-d of finishing, ADG was higher (P \u3c 0.10) for treatments 2 and 3 compared to 1, with treatment 4 being intermediate. Over the 133-d finishing trial, ADG of treatments 2 and 3 was greater (P \u3c 0.10) than treatment 1, with treatment 4 being intermediate, resulting in treatment 4 having lower carcass weight (P \u3c 0.05) compared to treatments 1, 2 and 3. Other carcass traits were not significantly different due to treatment. Steers receiving water during the growing period with 5000 ppm TDS and 3000 ppm sulfates or less were able to compensate for lost growing performance during the finishing period

    Characterization of anticoagulant heparinoids by immunoprofiling

    Get PDF
    Heparinoids are used in the clinic as anticoagulants. A specific pentasaccharide in heparinoids activates antithrombin III, resulting in inactivation of factor Xa and–when additional saccharides are present–inactivation of factor IIa. Structural and functional analysis of the heterogeneous heparinoids generally requires advanced equipment, is time consuming, and needs (extensive) sample preparation. In this study, a novel and fast method for the characterization of heparinoids is introduced based on reactivity with nine unique anti-heparin antibodies. Eight heparinoids were biochemically analyzed by electrophoresis and their reactivity with domain-specific anti-heparin antibodies was established by ELISA. Each heparinoid displayed a distinct immunoprofile matching its structural characteristics. The immunoprofile could also be linked to biological characteristics, such as the anti-Xa/anti-IIa ratio, which was reflected by reactivity of the heparinoids with antibodies HS4C3 (indicative for 3-O-sulfates) and HS4E4 (indicative for domains allowing anti-factor IIa activity). In addition, the immunoprofile could be indicative for heparinoid-induced side-effects, such as heparin-induced thrombocytopenia, as illustrated by reactivity with antibody NS4F5, which defines a very high sulfated domain. In conclusion, immunoprofiling provides a novel, fast, and simple methodology for the characterization of heparinoids, and allows high-throughput screening of (new) heparinoids for defined structural and biological characteristics

    1,25-Vitamin D3 Deficiency Induces Albuminuria

    No full text
    Vitamin D plays an important role in renal (patho)physiology. Patients with glomerular diseases have an injured renal filtration barrier, leading to proteinuria and reduced renal function. An impaired renal function also leads to 1,25-vitamin D3 deficiency as a result of reduced renal 1α-hydroxylase activity. Vitamin D treatment to reduce proteinuria remains controversial, although there is an inverse correlation between vitamin D levels and proteinuria. Herein, we showed that 1,25-vitamin D3-deficient 25-hydroxy-vitamin-D3-1α-hydroxylase knockout mice and 1,25-vitamin D3-deficient rats develop podocyte injury and renal dysfunction. Glomerular injury was characterized by proteinuria and partial podocyte foot process effacement. Expression of nephrin, podocin, desmin, and transient receptor potential channel C6 in the podocyte was significantly altered in 1,25-vitamin D3-deficient animals. Supplementation with 1,25-vitamin D3 or 1,25-vitamin D2 prevented podocyte effacement or reversed glomerular and tubulointerstitial damage in 1,25-vitamin D3-deficient animals, thereby preserving and restoring renal function, respectively. The effect of 1,25-vitamin D3 deficiency and 1,25-vitamin D3 and 1,25-vitamin D2 repletion on proteinuria could not be explained by hypocalcemia, changes in parathyroid hormone, or fibroblast growth factor 23. This study demonstrates that 1,25-vitamin D3 deficiency directly leads to renal injury in rodents. Translated to human subjects, this would underline the need for early vitamin D supplementation in patients with glomerular disease and chronic renal insufficiency, which might inhibit or potentially reverse renal injur

    A low molecular weight heparin inhibits experimental metastasis in mice independently of the endothelial glycocalyx

    Get PDF
    Contains fulltext : 88997.pdf (publisher's version ) (Open Access)BACKGROUND: Some low molecular weight heparins (LMWHs) prolong survival of cancer patients and inhibit experimental metastasis. The underlying mechanisms are still not clear but it has been suggested that LMWHs (at least in part) limit metastasis by preventing cancer cell-induced destruction of the endothelial glycocalyx. METHODOLOGY/PRINCIPAL FINDINGS: To prove or refute this hypothesis, we determined the net effects of the endothelial glycocalyx in cancer cell extravasation and we assessed the anti-metastatic effect of a clinically used LMWH in the presence and absence of an intact endothelial glycocalyx. We show that both exogenous enzymatic degradation as well as endogenous genetic modification of the endothelial glycocalyx decreased pulmonary tumor formation in a murine experimental metastasis model. Moreover, LMWH administration significantly reduced the number of pulmonary tumor foci and thus experimental metastasis both in the presence or absence of an intact endothelial glycocalyx. CONCLUSIONS: In summary, this paper shows that the net effect of the endothelial glycocalyx enhances experimental metastasis and that a LMWH does not limit experimental metastasis by a process involving the endothelial glycocalyx
    corecore